Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

NCT01229865 is registered in ClinicalTrials.gov with Vascular Biogenics Ltd. operating as VBL Therapeutics as lead sponsor.

NCT NCT01229865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01229865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
June 30, 2016
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

differential thyroid cancer